DermaSensor's handheld AI device, cleared by the FDA for primary-care use, detects the three most common skin cancers with 96% sensitivity, aiming to catch melanoma earlier outside dermatology offices.
Aureka Biotechnologies raised $100 million to build a 'biological world model' that simulates antibody design rather than just predicting protein structure, entering a crowded AI drug discovery funding field dominated by billion-dollar players.
A Minnesota federal judge ordered UnitedHealth to disclose internal documents on its nH Predict algorithm, which plaintiffs allege has a 90% error rate in denying Medicare Advantage patients' post-acute care.
California's SB 243, now eight months into enforcement, requires AI companion chatbots to detect suicidal ideation and gives users the right to sue directly — a first-in-the-nation law shaping a growing patchwork of state AI mental health regulation.
University of Pennsylvania researchers built ApexGO, a generative AI system that redesigns weak antibiotic peptide candidates, and two of its AI-optimized molecules matched last-resort antibiotic polymyxin B in mouse infection tests, according to a study published in Nature Machine Intelligence.
Johnson & Johnson's OTTAVA robotic surgery system completed a 30-patient gastric bypass trial with zero conversions to open surgery, marking its first human data after years of development.
New data presented at the American Heart Association's International Stroke Conference show Viz.ai's care-coordination platform cut door-in-door-out times for large vessel occlusion stroke patients by 44% at Adventist Health plus Rideout, nearly a 90-minute improvement over historical performance.
Alphabet's AI drug discovery spinout Isomorphic Labs closed a $2.1 billion Series B led by Thrive Capital in May 2026, one of the largest financings ever for an AI-first biotech, as it races toward its first human clinical trials by late 2026.
Google and microbiome company AMILI are launching AMILI Optimise, a nutrition app that replaces calorie counting with personalized recommendations based on gut microbiome data and measured blood glucose response, reflecting a broader industry shift toward biology-driven diet apps.
Woebot Health shut down its consumer AI therapy chatbot after years pursuing FDA marketing authorization it never received, with its founder blaming a regulatory process too slow for fast-moving AI — a cautionary tale now shadowing the whole AI mental health industry.